{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:05:15Z","timestamp":1776405915571,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"BioXcel Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12325-022-02274-3","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T17:03:13Z","timestamp":1661360593000},"page":"4821-4835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct04268303","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04276883","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-9266","authenticated-orcid":false,"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Risinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavanya","family":"Rajachandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Robison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"issue":"2","key":"2274_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/15622975.2015.1132007","volume":"17","author":"M Garriga","year":"2016","unstructured":"Garriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17(2):86\u2013128.","journal-title":"World J Biol Psychiatry"},{"key":"2274_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.psychres.2018.09.058","volume":"270","author":"E Sacchetti","year":"2018","unstructured":"Sacchetti E, Valsecchi P, Tamussi E, Paulli L, Morigi R, Vita A. Psychomotor agitation in subjects hospitalized for an acute exacerbation of Schizophrenia. Psychiatry Res. 2018;270:357\u201364.","journal-title":"Psychiatry Res"},{"issue":"Suppl 4","key":"2274_CR3","first-page":"3","volume":"64","author":"BS Alderfer","year":"2003","unstructured":"Alderfer BS, Allen MH. Treatment of agitation in bipolar disorder across the life cycle. J Clin Psychiatry. 2003;64(Suppl 4):3\u20139.","journal-title":"J Clin Psychiatry"},{"key":"2274_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fpsyt.2018.00054","volume":"9","author":"J Martinez-Raga","year":"2018","unstructured":"Martinez-Raga J, Amore M, Di Sciascio G, et al. 1st International experts\u2019 meeting on agitation: conclusions regarding the current and ideal management paradigm of agitation. Front Psychiatry. 2018;9:54.","journal-title":"Front Psychiatry"},{"issue":"1","key":"2274_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40268-019-0262-3","volume":"19","author":"B Pacciardi","year":"2019","unstructured":"Pacciardi B, Calcedo A, Messer T. Inhaled loxapine for the management of acute agitation in bipolar disorder and schizophrenia: expert review and commentary in an era of change. Drugs R D. 2019;19(1):15\u201325.","journal-title":"Drugs R D"},{"issue":"2","key":"2274_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.20299\/jpi.2018.008","volume":"14","author":"MX Patel","year":"2018","unstructured":"Patel MX, Sethi FN, Barnes TRE, et al. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: de-escalation and rapid tranquillisation. J Psychiatric Intensive Care. 2018;14(2):89\u2013132.","journal-title":"J Psychiatric Intensive Care"},{"issue":"2","key":"2274_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","volume":"70","author":"RL Wasserstein","year":"2016","unstructured":"Wasserstein RL, Lazar NA. The ASA Statement on p-values: context, process, and purpose. Am Stat. 2016;70(2):129\u201333.","journal-title":"Am Stat"},{"issue":"26","key":"2274_CR8","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","volume":"318","author":"A Laupacis","year":"1988","unstructured":"Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728\u201333.","journal-title":"N Engl J Med"},{"issue":"7168","key":"2274_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","volume":"317","author":"DG Altman","year":"1998","unstructured":"Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317(7168):1309\u201312.","journal-title":"BMJ"},{"issue":"5","key":"2274_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ijcp.12142","volume":"67","author":"L Citrome","year":"2013","unstructured":"Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407\u201311.","journal-title":"Int J Clin Pract"},{"issue":"12","key":"2274_CR11","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.4088\/JCP.v68n1207","volume":"68","author":"L Citrome","year":"2007","unstructured":"Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68(12):1876\u201385.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"2274_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1742-1241.2011.02890.x","volume":"66","author":"L Citrome","year":"2012","unstructured":"Citrome L. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. Int J Clin Pract. 2012;66(3):318\u201325.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"2274_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/acps.12262","volume":"130","author":"M Pratts","year":"2014","unstructured":"Pratts M, Citrome L, Grant W, Leso L, Opler LA. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand. 2014;130(1):61\u20138.","journal-title":"Acta Psychiatr Scand"},{"key":"2274_CR14","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13795","author":"L Citrome","year":"2021","unstructured":"Citrome L, Juday T, Frech F, Atkins N Jr. Lemborexant for the treatment of insomnia: direct and indirect comparisons with other hypnotics using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Clin Psychiatry. 2021. https:\/\/doi.org\/10.4088\/JCP.20m13795.","journal-title":"J Clin Psychiatry"},{"key":"2274_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jad.2020.03.106","volume":"271","author":"L Citrome","year":"2020","unstructured":"Citrome L, DiBernardo A, Singh J. Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2020;271:228\u201338.","journal-title":"J Affect Disord"},{"issue":"8","key":"2274_CR16","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1007\/s12325-021-01848-x","volume":"38","author":"L Citrome","year":"2021","unstructured":"Citrome L, S\u00e1nchez Del Rio M, Dong Y, et al. Benefit-risk assessment of galcanezumab versus placebo for the treatment of episodic and chronic migraine using the metrics of number needed to treat and number needed to harm. Adv Ther. 2021;38(8):4442\u201360.","journal-title":"Adv Ther"},{"issue":"8","key":"2274_CR17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40262-017-0507-7","volume":"56","author":"MAS Weerink","year":"2017","unstructured":"Weerink MAS, Struys M, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893\u2013913.","journal-title":"Clin Pharmacokinet"},{"key":"2274_CR18","first-page":"114","volume":"44","author":"SH Preskorn","year":"2019","unstructured":"Preskorn SH, Risinger R, Kakar R, Yocca FD. Double-blind, placebo-controlled, single ascending dose, study to determine the efficacy, safety, and pharmacokinetics of a BXCL501 (sublingual dexmedetomidine) in agitation associated with schizophrenia or related. Neuropsychopharmacology. 2019;44:114.","journal-title":"Neuropsychopharmacology"},{"key":"2274_CR19","unstructured":"Citrome L, Preskorn SH, Lauriello J, et al. Sublingual dexmedetomidine for the treatment of acute agitation in adults with schizophrenia or schizoaffective disorder: a randomized placebo-controlled trial. J Clin Psychiatry. (In Press)"},{"issue":"8","key":"2274_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jama.2022.0799","volume":"327","author":"SH Preskorn","year":"2022","unstructured":"Preskorn SH, Zeller S, Citrome L, et al. Effect of sublingual dexmedetomidine vs placebo on acute agitation associated with bipolar disorder: a randomized clinical trial. JAMA. 2022;327(8):727\u201336.","journal-title":"JAMA"},{"key":"2274_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7525-9-18","volume":"9","author":"A Montoya","year":"2011","unstructured":"Montoya A, Valladares A, Liz\u00e1n L, San L, Escobar R, Paz S. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes. 2011;9:18.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"2274_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.12788\/cp.0255","volume":"21","author":"L Citrome","year":"2022","unstructured":"Citrome L. Dexmedetomidine sublingual film for agitation. Curr Psychiatry. 2022;21(6):34\u20138.","journal-title":"Curr Psychiatry"},{"key":"2274_CR23","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: APA (American Psychiatric Association); 2013.","edition":"5"},{"key":"2274_CR24","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976."},{"issue":"4","key":"2274_CR25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S0893-133X(01)00365-7","volume":"26","author":"KM Meehan","year":"2002","unstructured":"Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26(4):494\u2013504.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"2274_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0735-6757(02)42249-8","volume":"21","author":"J Battaglia","year":"2003","unstructured":"Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med. 2003;21(3):192\u20138.","journal-title":"Am J Emerg Med"},{"issue":"6","key":"2274_CR27","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","volume":"117","author":"L Citrome","year":"2008","unstructured":"Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117(6):412\u20139.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"2274_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1600-0447.2009.01449.x","volume":"121","author":"L Citrome","year":"2010","unstructured":"Citrome L. Relative vs. absolute measures of benefit and risk: what's the difference? Acta Psychiatr Scand. 2010;121(2):94\u2013102.","journal-title":"Acta Psychiatr Scand"}],"updated-by":[{"DOI":"10.1007\/s12325-022-02350-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02274-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02274-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02274-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T22:05:55Z","timestamp":1667253955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02274-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["2274"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02274-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12325-022-02350-8","asserted-by":"object"}]},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-022-02350-8","URL":"https:\/\/doi.org\/10.1007\/s12325-022-02350-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}